Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18730546 | 0.89 | TDP1 (0.61) | ACHETDP1L3MBTL1SIGMAR1 | |
| SCHEMBL7946668 | 0.85 | ACHE (0.74) | ACHE | |
| SCHEMBL9827604 | 0.85 | ACHE (0.69) | ACHE | |
| SCHEMBL5683558 | 0.84 | ACHE (0.56) | ACHE | |
| SCHEMBL916601 | 0.84 | TDP1 (0.96) | ACHETDP1L3MBTL1 | |
| SCHEMBL9218494 | 0.84 | ACHE (0.66) | ACHE | |
| SCHEMBL31035964 | 0.82 | TDP1 (1.00) | ACHETDP1L3MBTL1 | |
| SCHEMBL29263641 | 0.82 | TDP1 (1.00) | ACHETDP1L3MBTL1 | |
| SCHEMBL9219707 | 0.82 | TDP1 (1.00) | ACHETDP1L3MBTL1 | |
| SCHEMBL8434811 | 0.82 | TDP1 (1.00) | ACHETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | disclosed |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE II DROIT & SANTE (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2020-11-24 | — | — | US | disclosed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | disclosed |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-01-15 | — | — | US | disclosed |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
| EP-3154934-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015193255-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-23 | — | — | WO | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | ACHE 4165/4885TDP1 4526/4885L3MBTL1 4570/4885 |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | ACHE 15/4885TDP1 216/4885L3MBTL1 4606/4885 |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | ACHE 15/4885TDP1 216/4885L3MBTL1 4606/4885 |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | ACHE 15/4885TDP1 216/4885L3MBTL1 4606/4885 |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | ACHE 15/4885TDP1 216/4885L3MBTL1 4606/4885 |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | ACHE 15/4885TDP1 216/4885L3MBTL1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.